Improving combination cancer immunotherapy by manipulating dual immunomodulatory signals with enzyme-triggered, cell-penetrating peptide-mediated biomodulators-Reference-Cited by-同舟云学术

Improving combination cancer immunotherapy by manipulating dual immunomodulatory signals with enzyme-triggered, cell-penetrating peptide-mediated biomodulators

Published:2024 Issue:3 Volume:12 Page:776-789
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Pang Guibin¹,Chen Piao¹,Cao Xuewei¹²,Yu Huan³,Zhang Leshuai W.³^ORCID,Zhao Jian¹²^ORCID,Wang Fu-Jun⁴²⁵^ORCID

Affiliation:

1. State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, P. R. China

2. ECUST-FONOW Joint Research Center for Innovative Medicines, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, P. R. China

3. School for Radiological and Interdisciplinary Sciences (RAD-X), State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China

4. New Drug R&D Center, Zhejiang Fonow Medicine Co., Ltd., 209 West Hulian Road, Dongyang 322100, Zhejiang, P. R. China

5. Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, P. R. China

Abstract

Bifunctional chimeric protein containing PP1-disrupting sequence induced calreticulin exposure and reversed immunosuppressive tumor microenvironment, thereby enhancing antitumor effect.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2024/BM/D3BM01605F

Reference42 articles.

1. Combination immunotherapy: a road map

2. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

3. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

4. Recent progress in TGF-β inhibitors for cancer therapy

5. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The battle within: cell death by phagocytosis in cancer;Clinical and Translational Oncology;2024-08-21